What does 908 Devices do and what are its main business segments?

What guidance did 908 Devices's management provide for the next earnings period?

Did 908 Devices beat or miss consensus estimates last quarter?

What were the key takeaways from 908 Devices's earnings call?

What is the market's earnings forecast for 908 Devices next quarter?

What is 908 Devices's latest dividend and current dividend yield?

What were the key takeaways from 908 Devices’s earnings call?

What factors drove the changes in 908 Devices's revenue and profit?

- **Revenue Resilience**: Q3 $14M (-4% YoY) with 30% QoQ jump in Explorer shipments. Recurring revenue at 36% of total, up 10% YoY.
- **Profitability Milestone**: Adjusted EBITDA loss of $1.8M (-53% QoQ), targeting Q4 positivity. Gross margin 58% (adjusted) from Danbury scale-up.
- **Strategic Growth**: VIPER secures 35 Q4 units; AVCAD field validation complete. 2026 targets 20%+ revenue growth with NextGen MX launch.
- **Government Risk**: $4M Q4 revenue at risk from federal delays, but 2026 pipeline remains robust with international and state/local demand.

**【CEO Summary Section】**
- **Revenue Performance**: Q3 revenue of $14 million (-4% YoY, +8% QoQ) driven by FTIR devices, with Explorer shipments up 30% QoQ. Installed base grew to 3,512 devices (+27% YoY). Recurring revenue at 36% of total, up 10% YoY.
- **Strategic Wins**: U.S. Coast Guard purchased 23 MX908 devices; Explorer placements in 9+ countries. Q4 pipeline includes 35 VIPER units and 60+ enterprise devices.
- **Profitability Progress**: Adjusted EBITDA loss of $1.8 million (-32% YoY, -53% QoQ), targeting Q4 EBITDA positivity. Gross margin improved to 58% (adjusted) due to Danbury facility scale-up.
- **Government Impact**: $4M Q4 revenue at risk from U.S. federal delays, but 2026 outlook remains strong with VIPER, Explorer, and AVCAD growth drivers.

**【CFO Financial Commentary】**
- **Top Line**: Handheld revenue $13.2M (-5% YoY), recurring revenue $4.8M (+10% YoY). VIPER and Explorer driving diversification.
- **Margins & Costs**: Gross margin 53% (58% adjusted), down 60bps YoY due to product mix. Operating expenses down $8.4M YoY (excluding non-cash items). Cash of $112M, no debt.
- **Guidance**: Full-year revenue $54-56M (+13-17% YoY). 2026 outlook includes NextGen MX launch and Team Leader software monetization.

**【Q&A Key Highlights】**
- **Government Shutdown Risks**: $3M federal orders delayed; $1M international exports impacted. 2026 carryover potential if unresolved.
- **AVCAD Program**: Field validation complete; next phase clarity expected by year-end. Long-term 5-7 year growth horizon.
- **VIPER Momentum**: 35 Q4 shipments; no MX cannibalization. Team Leader software to add recurring revenue via fleet management features.
- **2026 Outlook**: Target 20%+ revenue growth with VIPER, Explorer, and AVCAD. EBITDA sustainability hinges on Q4 execution and 2026 scale.

908 Devices Inc. (MASS) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: $13M Q2 revenue (+14% YoY), driven by handheld devices and legislative funding.
- **Profitability Progress**: Adjusted EBITDA loss of $3.9M (45% YoY improvement), targeting Q4 EBITDA breakeven.
- **Innovation Momentum**: VipIR launch and MX908 fentanyl detection capabilities expand market reach.
- **Funding Tailwinds**: $1.7B+ grants and NATO defense spending to support 20%+ 2026 growth.
- **Operational Efficiency**: 44% facility reduction, KAF acquisition, and $118.6M cash balance strengthen margins.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $13 million, up 14% YoY, driven by handheld device sales (60% of revenue) and FKR products (40%).
- **Adjusted EBITDA Improvement**: Loss of $3.9 million, 45% better YoY and 15% QoQ reduction, with target to reach EBITDA positive by Q4 2025.
- **Strategic Focus Areas**: 
  1. **Market Expansion**: Legislative funding ($1.7B+ in grants) supports growth, including $760M for COPS/Byrne JAG and $900M for event security (e.g., 2026 FIFA World Cup).
  2. **Innovation**: Launched VipIR (3-in-1 chemical analyzer) and MX908 for fentanyl detection (2,000+ analogs).
  3. **Financial Discipline**: 44% facility space reduction, 39% headcount cut, and $2.75M KAF acquisition to in-source components.
- **Product Performance**: 164 devices placed (record 45 XplorIR units), with 3,336 installed base.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: 
  - Handheld products/services: $12.5M (13% YoY)
  - OEM/partnerships: $0.5M
  - Recurring revenue: $4.7M (36% of total, +28% YoY)
- **Gross Margin**: 49% (down 5pp YoY due to intangible amortization and warranty costs).
- **Operating Expenses**: $21.5M (+46% YoY) driven by non-cash charges and RedWave acquisition costs.
- **Cash Position**: $118.6M, with 2025 revenue guidance updated to $54-56M (13-17% YoY growth).
- **2026 Outlook**: Target 20%+ revenue growth, mid-50s%+ gross margin, and EBITDA breakeven.

**【Q&A Highlights】**
- **Legislative Tailwinds**: FY26 funding ($1.7B+ grants) and NATO defense spending (5% GDP target) to boost device adoption.
- **VipIR Uptake**: Early feedback positive; expected 2026 pilot/enterprise opportunities.
- **XplorIR Growth**: 45 units funded via firefighter grants, with 11% YoY grant funding increase.
- **Manufacturing Capacity**: Danbury facility (40,000 sqft) supports MX908 2.0 production with minimal CapEx.
- **AVCAD Program**: Potential $10M+ annual revenue from 2026 full-rate production award.

908 Devices Inc. (MASS) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q1 2025 revenue from continuing ops up 59% YoY to $11.8M, driven by handheld device adoption (60%) and FTIR products (40%). Recurring revenue now 37% of total.
- **Strategic Wins in Public Safety**: $2M Texas DPS order and EU rescEU program expansions highlight growing public safety demand. U.S. federal agencies added 12 MX908 units, total deployment now 65.
- **AVCAD Program Catalyst**: Full-rate production decision expected by end-2025 gov fiscal year, with potential $10M+ annual revenue from 2026 onward.
- **Profitability Path**: Target Q4 2025 adjusted EBITDA positivity and 2026 cash flow breakeven. $70M biopharma sale bolsters cash to $124.3M, supporting Danbury production consolidation ($2M/year savings).

**【CEO Summary Section】**
- **Strategic Transformation Success**: Q1 2025 revenue from continuing operations rose 59% YoY to $11.8 million, driven by handheld device sales (60%) and FTIR products (40%). Recurring revenue grew 54% to $4.4 million, accounting for 37% of total revenue.
- **Market Expansion Momentum**: Secured $2 million order from Texas DPS for MX908 devices, expanding state and local adoption. EU rescEU program orders (e.g., Finland, Czech Republic) highlight international growth. U.S. federal agencies (HSI) added 12 MX908 units, bringing total deployment to 65.
- **Innovation Pipeline**: Launched software update for ProtectIR with advanced mixture analysis. On track for 2026 launch of next-gen handheld mass spec and FTIR devices. AVCAD program expects full-rate production by end-2026, potentially generating $10M+ annual revenue.
- **Financial Discipline**: Targeting Q4 2025 adjusted EBITDA positivity and 2026 cash flow breakeven. $70M biopharma sale to Repligen strengthened cash to $124.3M, enabling production consolidation in Danbury, CT (expected Q2 2025 completion). Facility cost savings of $2M/year begin Q3 2025.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: GAAP net loss from continuing ops was $9.8M (vs. $5.9M YoY), driven by $2.5M non-cash contingent consideration charge. Adjusted EBITDA loss improved 50% YoY to $4.6M. Gross margin was 47% (52% YoY), with adjusted gross margin at 54% (up 75bps YoY).
- **Revenue Breakdown**: Handheld product/service revenue grew 86% YoY to $11M, driven by FTIR product integration. OEM/partnership revenue rose to $0.7M (vs. $0 in Q1 2024). Program revenue (AVCAD) declined to $0.1M (vs. $1.5M YoY).
- **Guidance**: Full-year 2025 revenue expected $53-55M (11-15% YoY growth). Adjusted gross margin to expand to mid- to high-50% range. 2026 targets: >20% revenue growth, adjusted EBITDA positive, and cash flow breakeven.

**【Q&A Key Themes】**
- **RedWave Integration**: Cross-selling success (e.g., Texas DPS follow-on orders) validates FTIR/mass spec portfolio synergy. Sales team of 40+ is well-positioned to capitalize on global demand.
- **AVCAD Program**: Full-rate production decision expected by end-2025 gov fiscal year. Potential $10M+ annual revenue from 2026 onward, contingent on U.S. DoD approval.
- **Danbury Transition**: Manufacturing move on track for Q2 2025 completion. $2M/year facility savings begin Q3 2025, with 40% of benefits flowing through gross margin.
- **Government Contract Visibility**: State/local and international pipeline supports back-half 2025 growth. U.S. federal military engagement aligns with national security priorities (e.g., drug interdiction, chemical detection).
- **M&A Strategy**: Open to synergistic opportunities but focused on executing organic growth plan. 2026+ pipeline includes next-gen MX device and FTIR innovations.

908 Devices (MASS)-13 May 25-2025 Q1 Earnings call transcript

- **$70M Desktop Divestiture**: Doubling cash to $110M, enabling 2026 cash flow breakeven and focus on 11-15% handheld growth.
- **Q4 2024 Strong Performance**: $18.8M revenue (+31% YoY), driven by FTIR and MX908 international orders.
- **2025 Outlook**: $53-55M revenue, 55%+ gross margin, and Q4 EBITDA positivity.
- **Key Catalysts**: 15,000 FTIR upgrades, 700-unit pilot pipeline, and 2026 MX908 upgrade cycle.
- **AVCAD Opportunity**: $10M+ annual revenue potential from full-rate production in 2026.


**【CEO Strategic Transformation】**
- Announced divestiture of desktop bioprocessing portfolio to Repligen for $70 million, nearly doubling cash reserves to $110 million by end of 2025.
- Focused on high-growth handheld markets (opioid crisis response, defense, border security) with 2025 revenue guidance of $53-55 million (11-15% YoY growth).
- Expected adjusted EBITDA positivity by Q4 2025 and cash flow breakeven in 2026.

**【CFO Financial Highlights】**
- Q4 2024 revenue: $18.8 million (+31% YoY), driven by handheld devices (MX908, FTIR) and international orders (e.g., Finland, Romania).
- Full year 2024 revenue: $59.6 million (+19% YoY), with handhelds contributing $46.1 million (+22% YoY).
- Adjusted gross margin: 55% in 2024, targeting mid- to high-50s in 2025.
- Net loss for 2024: $72.2 million due to $40.7 million goodwill impairment charge.

**【Q&A Key Takeaways】**
- **Bioprocessing Divestiture**: Repligen assumed 450-unit installed base, 1/3 headcount reduction, and $70 million cash injection.
- **Handheld Growth Catalysts**: 15,000 outdated FTIR units up for modernization, 700-unit pilot pipeline, and 2026 MX908 upgrade cycle.
- **Pharma & OEM Expansion**: 5% of 2025 revenue from partnerships (e.g., Repligen, industrial QA/QC), with potential for future growth.
- **Tariff Risks**: Monitoring Canada/Mexico tariffs but minimal U.S.-based supply chain exposure.
- **AVCAD Program**: Full-rate production notice expected in 2025, potential $10+ million annual revenue.


908 Devices (MASS)-4 Mar 25-2024 Q4 Earnings call transcript

908 Devices (MASS)-12 Nov 24-2024 Q3 Earnings call transcript

908 Devices (MASS)-6 Aug 24-2024 Q2 Earnings call transcript

908 Devices (MASS)-30 Apr 24-2024 Q1 Earnings call transcript

908 Devices (MASS)-5 Mar 24-2023 Q4 Earnings call transcript

908 Devices (MASS)-7 Nov 23-2023 Q3 Earnings call transcript

908 Devices (MASS)-8 Aug 23-2023 Q2 Earnings call transcript

908 Devices (MASS)-9 May 23-2023 Q1 Earnings call transcript

908 Devices (MASS)-7 Mar 23-2022 Q4 Earnings call transcript

908 Devices (MASS)-14 Nov 22-2022 Q3 Earnings call transcript

908 Devices (MASS)-9 Aug 22-2022 Q2 Earnings call transcript

908 Devices (MASS)-10 May 22-2022 Q1 Earnings call transcript

- **Revenue surge**: 57% YoY growth to $42.2M, driven by 163% YoY MX908 sales.
- **Biopharma traction**: 45% of REBEL placements in cell/gene therapy, up from 22%.
- **2022 outlook**: $52-55M guidance (23-30% growth), 2/3 in H2 due to govt/pharma cycles.
- **Key risks**: U.S. budget delays, international COVID-19 restrictions.
- **Proteomics progress**: R&D project with attomolar sensitivity demonstrated at HUPO.

**【CEO Summary Section】**
- Q4 2021 revenue: $15.8 million (57% YoY growth to $42.2 million annually). Handheld MX908 revenue up 163% YoY, driven by U.S. Army contracts.
- Installed base: 19,135 devices (221 units shipped in Q4). 45% of REBEL placements in cell/gene therapy, up from 22% YoY.
- Key partnerships: 60 commercial employees across 12 countries; 10 pilot programs for enterprise adoption.
- 2022 focus: Expand sales team to 80, penetrate biopharma with REBEL, and develop proteomics capabilities.

**【CFO Financial Commentary】**
- Q4 2021: GAAP net loss $3.5 million; full year $22.2 million. Cash: $224 million (including $94M from Nov 2021 follow-on).
- 2022 guidance: $52-55 million revenue (23-30% YoY growth). 2/3 of revenue expected in H2 due to U.S. govt/Q4 pharma cycles.
- Gross margin: 58% (Q4) vs. 45% (2020). Operating expenses up 95% YoY due to headcount expansion.

**【Q&A Highlights】**
- **Market demand**: Opioid crisis driving MX908 adoption (e.g., Ohio AG's 100+ fentanyl identifications). Biopharma 4.0 needs real-time analytics for advanced therapies.
- **Sales pipeline**: 50%+ growth in desktop sales pipeline. 700+ potential units in enterprise accounts.
- **Risks**: U.S. govt budget delays, COVID-related international travel constraints.
- **REBEL pull-through**: 40% active users; targeting 1 kit/month per device. New placements expected to boost recurring revenue.
- **Proteomics**: R&D project; no 2022 contribution. Recent HUPO presentation shows attomolar sensitivity in minutes.

MASS

MASS fundamentals

Earnings Call

You can ask Aime